Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/28/2025 | $42.00 | Neutral → Buy | BofA Securities |
| 3/10/2025 | $40.00 | Sector Perform → Sector Outperform | Scotiabank |
| 1/29/2025 | Neutral → Overweight | Cantor Fitzgerald | |
| 11/6/2024 | $27.00 → $39.00 | Market Perform → Outperform | Leerink Partners |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 7/23/2024 | $80.00 | Buy | H.C. Wainwright |
| 1/29/2024 | $38.00 → $40.00 | Neutral → Overweight | JP Morgan |
| 12/15/2023 | $35.00 | Buy → Neutral | BofA Securities |
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
4 - Beam Therapeutics Inc. (0001745999) (Issuer)
CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "We are thrilled that the FDA has granted RMAT designation to BEAM-101, following orphan drug designation earlier this year, reinforcing its potential as a one-time, best-in-class therapy for severe sickle cell disease," said Giuseppe Ciaramella, Ph.D., pre
With 17 Patients Dosed in the Phase 1/2 Trial, BEAM-302 Continues to Demonstrate Durable Correction of the Disease-causing Mutation, Restoration of AAT Physiology, and a Well Tolerated Safety Profile BEAM-302 Expanded Dose Exploration Underway in Part A and Enrollment Initiated in Part B; Data from Parts A and B of the Phase 1/2 Trial and Clinical Development Update Expected in Early 2026 Dosing Complete for 30 Sickle Cell Disease Patients and First Adolescent Patient Dosed in BEACON Phase 1/2 Trial of BEAM-101; Updated Data Expected by End of 2025 Ended Second Quarter 2025 with $1.2 Billion in Cash, Cash Equivalents and Marketable Securities; Cash Runway Expected to Support O
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL
BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00
Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00
Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight
SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
10-Q - Beam Therapeutics Inc. (0001745999) (Filer)
CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo
CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o
CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d
Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL
Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge
Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)
SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)